Full-Time

CWI

Deadline 3/11/27
JANX

JANX

51-200 employees

No salary listed

No H1B Sponsorship

Raleigh, NC, USA

In Person

Category
QA & Testing (1)
Requirements
  • High school diploma or equivalent is required
  • 2 years of CWI experience is required
  • Experience in NDT industry preferred
  • Employees must be legally authorized to work in the United States; visa sponsorship is not available for this position
  • CWI certification is required
  • Must meet minimum company requirements to operate a company vehicle and be eligible for coverage under the company insurance program
Responsibilities
  • Perform complete nondestructive testing field inspections based on customer requirements and procedures, JANX field procedures, focusing on quality and safety
  • Perform advanced field inspections such as CWI in the crane and structural inspection markets, based on customer requirements and procedures, JANX field procedures and being able to fully operate and interpret results based on advanced NDT methods
  • Ensure all equipment is set up, calibrated, and functional at all times in line with JANX and customer procedures
  • Operate advanced NDT equipment including calibration, field execution and basic troubleshooting to ensure compliance and quality at all times while performing work
  • Apply testing criteria in accordance with applicable specifications, both conventional and advanced NDT
Desired Qualifications
  • NDT experience preferred
  • Experience in NDT inspections for the structural and crane inspection markets, preferred

Company Size

51-200

Company Stage

N/A

Total Funding

N/A

Headquarters

Parma, Ohio

Founded

1981

Simplify Jobs

Simplify's Take

What believers are saying

  • BMS collaboration provides $35M upfront plus development, regulatory, and commercial milestones.
  • JANX008 Phase 1 enrollment and JANX011 first-in-human dosing advance clinical validation.
  • Tumor-activated approach reduces off-target toxicity versus conventional T cell therapies.

What critics are saying

  • BMS termination or deprioritization eliminates material funding and validation signal.
  • JANX011 Phase 1 adverse events or efficacy failure damages platform credibility.
  • Clinical-stage biotech requires continuous capital raises; market downturns force dilution.

What makes JANX unique

  • TRACTr platform selectively activates T cells against tumor antigens with precision engineering.
  • Dual-pipeline approach targets both cancer and autoimmune diseases with same core technology.
  • Bristol Myers Squibb validation and $35M milestone payment demonstrate platform credibility.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at JANX who can refer or advise you

Benefits

Health Insurance